DNA X, Inc. Quarterly report [Sections 13 or 15(d)]

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2026

Stock-based compensation expense is as follows (in thousands of dollars):

	2026		2025		2026		2025
	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2026		2025		2026		2025
Cost of revenues	$	—	$	13	$	13	$	15
Research and development		—		12		20		14
Sales and marketing		—		329		60		394
General and administrative		98		572		309		793
Stock-based compensation expenses	$	98	$	926	$	402	$	1,216

Stock option activity for the six months ended June 30, 2026, is set forth in the table below (price per share is in dollars):

Schedule of Stock Option Activity

	Options			Weighted average exercise price per share		Weighted average remaining contractual life (in years)		Aggregate Intrinsic Value*
Outstanding at January 1, 2026		34,883		$	110.67
Granted		—			—
Exercised		—			—
Forfeited and Expired		(32,162	)		110.52
Outstanding at June 30, 2026		2,721		$	112.53		7.38	$	—
Vested and Expected to Vest at June 30, 2026		2,721		$	112.53		7.38	$	—
Exercisable at June 30, 2026		2,374		$	112.79		7.32	$	—

The intrinsic value is calculated as the difference between the exercise price and the fair value of the common stock on the balance sheet date.

Restricted Stock Unit (“RSU”) activity for the six months ended June 30, 2026, is set forth in the table below:

Warrants activity, as adjusted for the Reverse Stock Split, for the three months ended June 30, 2026, is as follows:

Schedule of Warrant Activity

	Number of warrants		Weighted average exercise price per share
Outstanding at January 1, 2026		62,979	$	13.75
Granted		—		—
Forfeited		—		—
Expired		—		—
Outstanding at June 30, 2026		62,979	$	13.75
Exercisable at June 30, 2026		62,979	$	13.75